HEPA Stock Summary and Trading Ideas (Hepion Pharmaceuticals | NASDAQ:HEPA)

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals trades on the NASDAQ stock market under the symbol HEPA.

As of April 19, 2024, HEPA stock price declined to $2.01 with 34,007 million shares trading.

HEPA has a beta of 0.98, meaning it tends to be less sensitive to market movements. HEPA has a correlation of 0.01 to the broad based SPY ETF.

HEPA has a market cap of $8.72 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, HEPA stock traded as high as $46.37 and as low as $1.49.

The top ETF exchange traded funds that HEPA belongs to (by Net Assets): VTI, VXF.

HEPA has underperformed the market in the last year with a price return of -87.2% while the SPY ETF gained +21.2%. HEPA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.9% and -23.9%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

HEPA support price is $1.97 and resistance is $2.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HEPA stock will trade within this expected range on the day.